Actinogen Medical Ltd ACW
News
Actinogen pivotal Alzheimer’s disease trial demonstrates clinical benefit in older patients with mild to moderate disease, favorable safety profile and trends towards benefit in the overall population
Actinogen pivotal Alzheimer’s disease trial database lock milestone - topline results on track for mid-November
Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
Trading Information
- Previous Close Price
- A$0.01
- Day Range
- A$0.01–0.01
- 52-Week Range
- A$0.01–0.07
- Bid/Ask
- A$0.01 / A$0.01
- Shares Outstanding
- 3.87B
- Market Cap
- A$34.83M
- Volume/Avg
- 54M / 10M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- https://www.actinogen.com.au
Valuation
Metric | ACW |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.39 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ACW |
|---|---|
Quick Ratio | 3.44 |
Current Ratio | 3.45 |
Interest Coverage | — |
Quick Ratio
ACW
Profitability
Metric | ACW |
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ACW
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|v^!n?^Y | LOCK|&qHZ | $132B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|P<VR!$ | LOCK|GT!k | $96B | |||
| Moderna Inc MRNA | LOCK|T<&%rm? | LOCK|F^ | $81B | |||
| argenx SE ADR ARGX | LOCK|G@Y@?N | LOCK|KXG | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|w@!Bnn@ | LOCK|>qH | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^!<<w&n | LOCK|Z%Yb< | $30B | |||
| Incyte Corp INCY | LOCK|fqVRN^ | LOCK|y?y | $24B | |||
| BioNTech SE ADR BNTX | LOCK|xKl?k% | LOCK|N? | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|#%XTxm | LOCK|q<<!J | $20B | |||
| BridgeBio Pharma Inc BBIO | LOCK|!tsl$Y | LOCK|T^& | $15B |